MyMD Pharmaceuticals, Inc. (MYMD)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.2400 |
| Open | 2.2500 |
| Bid | 2.0400 x 1000 |
| Ask | 2.3100 x 1000 |
| Day's Range | 2.0000 - 2.3600 |
| 52 Week Range | 1.8800 - 9.9500 |
| Volume | |
| Avg. Volume | 69,112 |
| Market Cap | 77.162M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8120 |
| Earnings Date | Feb 28, 2022 - Mar 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan
BALTIMORE, June 21, 2022--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced further advancement in its fully-funded, multi-center Phase 2 clinical trial of lead drug candidate MYMD-1® as a therapy for delaying aging and expanding healthy lifespan. All clinical trial sites, including a world leading academic institution, are now enrolling patients.
- Business Wire
MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan
BALTIMORE, Md., April 05, 2022--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced an acceleration in the pace of new patient dosing in the Company’s fully funded Phase 2 clinical trial of lead drug candidate MYMD-1 as a therapy for delaying aging and expanding healthy lifespan. The Phase 2 double-blind, placebo controlled, randomized study (NCT05283486) investigates the efficacy, t
- Business Wire
MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24
BALTIMORE, March 24, 2022--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that Dr. Adam Kaplin, Chief Scientific Officer, will appear as a featured guest on the Cheddar News Network show "Cheddar Innovates" on Thursday, March 24th, 2022 at 11:50am ET.
